Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22469818 | 1.00 | PARP1 (0.63) | PARP1PARP10PARP11ACHEPDPK1 | |
| SCHEMBL7582290 | 0.85 | PARP1 (0.65) | PARP1PARP10PARP11ACHEPDPK1 | |
| SCHEMBL15474121 | 0.83 | PARP1 (0.58) | PARP1PARP10PARP11ACHEPDPK1 | |
| SCHEMBL20627541 | 0.80 | PARP1 (0.58) | PARP1PARP10PARP11ACHEPDPK1 | |
| SCHEMBL830807 | 0.77 | PARP1 (1.00) | PARP1PARP10PARP11ACHEPDPK1 | |
| SCHEMBL26162802 | 0.76 | PARP10 (0.56) | PARP1PARP10PARP11PDPK1MRGPRX4 | |
| SCHEMBL30775223 | 0.75 | CLK4 (0.51) | PARP1PARP10PARP11 | |
| SCHEMBL29974199 | 0.75 | NOTUM (0.40) | PARP1PARP10PARP11ACHE | |
| SCHEMBL3884626 | 0.75 | NOTUM (0.40) | PARP1PARP10PARP11ACHE | |
| SCHEMBL27883759 | 0.75 | PARP1 (0.65) | PARP1PARP10PARP11ACHEPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115397412-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-03-25 | — | — | CN | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PARP1 4386/4885PARP10 2728/4885PARP11 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.